AbbVie's Allergan to Buy Luminera Dermal-Filler Business
October 07 2020 - 10:33AM
Dow Jones News
By Colin Kellaher
AbbVie Inc.'s Allergan Aesthetics unit on Wednesday said it
agreed to buy the dermal-filler portfolio and
research-and-development pipeline of Luminera, a privately held
Israeli aesthetics company, for an undisclosed amount.
Allergan, which AbbVie acquired earlier this year in a $63
billion deal, said the acquisition enhances its portfolio with the
addition of HArmonyCa, a filler intended for facial soft-tissue
augmentation that combines hyaluronic acid and calcium
hydroxyapatite.
Allergan said HArmonyCa is currently commercially available in
Israel and Brazil, and that it will continue to develop the product
for the U.S. and other international markets.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 07, 2020 10:18 ET (14:18 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
